First Participant Enrolled in Phase 2b Trial of Petrelintide
Zealand Pharma A/S (NASDAQ: ZEAL) has taken a significant step in the development of innovative treatments for individuals struggling with overweight or obesity alongside type 2 diabetes. The company has officially enrolled its first participant in the Phase 2b ZUPREME-2 trial, centered on the efficacy and safety of petrelintide. This advancement highlights Zealand Pharma's commitment to improving health outcomes through groundbreaking peptide-based therapies.
Overview of the ZUPREME-2 Trial
The Phase 2b ZUPREME-2 trial is designed to rigorously assess the effects of petrelintide, a long-acting amylin analog, administered subcutaneously once a week. This study aims to evaluate three varying doses of the drug, culminating at 9 mg, over a period of 28 weeks. By focusing on participants with overweight or obesity and type 2 diabetes, the trial aims to document significant changes in weight and overall health.
Trial Structure and Methodology
This randomized, double-blind, placebo-controlled trial will include a diverse group of around 200 participants. The study plan consists of several phases: a screening period, an escalating dose treatment period spanning 16 weeks, followed by a maintenance treatment phase lasting until week 28. Data will also be collected in a follow-up phase, lasting until week 38.
Evaluating Critical Outcomes
The primary goal of the trial is to determine the percentage change in body weight from baseline to week 28, while secondary endpoints will explore additional metrics. These metrics include body weight loss goals and modifications in waist circumference and glycemic indicators such as hemoglobin A1c (HbA1c) levels. This comprehensive approach underscores Zealand Pharma’s dedication to providing valuable insights into effective weight management strategies.
Insights from Zealand Pharma Leadership
David Kendall, MD, Chief Medical Officer at Zealand Pharma, expressed enthusiasm about the trial’s initiation. He stated, “ZUPREME-2 represents the second Phase 2 trial that we’re launching with petrelintide, reinforcing our clinical development plan to position this drug as a leading option among incretin-based therapies for weight management.” His remarks highlight the potential of amylin agonism in achieving clinically meaningful weight loss.
About Petrelintide and Its Development
Petrelintide is engineered for once-weekly subcutaneous administration, showcasing a unique formulation that ensures chemical and physical stability without fibrillation at neutral pH. The drug operates by activating amylin receptors, significantly enhancing the body's sensitivity to the hormone leptin, which plays a crucial role in signaling satiety.
Comparative Potential with Existing Therapies
Current studies suggest that petrelintide may provide weight loss comparable to GLP-1 receptor agonists while offering improved tolerability. This characteristic could lead to a more favorable patient experience, enhancing adherence to treatment plans.
Future Directions and Collaborations
Looking ahead, Zealand Pharma's strategic partnerships amplify its research capabilities. A recent collaboration with Roche aims to co-develop and commercialize petrelintide, underlining the shared goal of establishing this therapy as a foundational treatment in managing obesity effectively. Both companies anticipate the completion of necessary regulatory approvals, paving the way for a promising future.
About Zealand Pharma
Founded in 1998 and based in Copenhagen, Denmark, Zealand Pharma A/S is at the forefront of developing peptide-based medicines. With over ten drug candidates advancing through clinical development, including several that have reached the market, the company continues to expand its partnerships within the pharmaceutical industry, enhancing its commitment to innovative healthcare solutions.
Frequently Asked Questions
What is the ZUPREME-2 trial focused on?
The ZUPREME-2 trial is centered on evaluating the efficacy and safety of petrelintide in participants with overweight or obesity and type 2 diabetes.
How many participants are expected to enroll in the trial?
Approximately 200 participants are anticipated to enroll in the ZUPREME-2 trial.
What are the primary goals of the trial?
The primary goal is to assess the percentage change in body weight from baseline to week 28, with several secondary endpoints including body weight loss and improvements in glycemic indicators.
What is petrelintide?
Petrelintide is a long-acting amylin analog intended for weekly subcutaneous administration, designed to enhance satiety and support weight management.
What collaborations enhance Zealand Pharma's development?
Zealand Pharma's collaboration with Roche aims to co-develop petrelintide, focusing on its potential in obesity management.
